

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF T
04 FEB 20 PI

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Beau Dietl and Associates			
2. Address <input type="checkbox"/> Check if different than previously reported 220 East 42nd Street, Suite 3500			
3. Principal Place of Business (if different from line 2) New York City: New York State/zip (or Country): New York 10017			
4. Contact Name Julie Corcoran	Telephone (202) 835-3523	E-mail (optional) jcorcoran@phrma.org	5. Senate ID #
7. Client Name <input type="checkbox"/> Self Pharmaceutical Research and Manufacturers of America			6. House ID #

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____

11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>\$22,000.00</u> Income (nearest \$20,000)	\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of
	<input type="checkbox"/> Method A. Reporting amounts using LDA definition
	<input type="checkbox"/> Method B. Reporting amounts under section 6033 Internal Revenue Code
	<input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code

alix

Signature _____ Date _____

Printed Name and Title **Richard Dietl, Chairman**

**Pharmaceutical Research and
Manufacturers of America**

Registrant Name Beau Dietl and Associates Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which th
engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each co
information as requested. Attach additional page(s) as needed.

15. General issue area code CSP (one per page)

16. Specific lobbying issues

H.R. 616	H.R. 2427	H.R. 2717	S.B.477
H.R. 780	H.R. 2491	H.R. 3710	S.B. 1225
H.R. 847	H.R. 2497	S.B. 7	
H.R. 1733	H.C.R. 225	S.B. 54	

Please see attached


17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Richard Dietl	
Michael Ciravolo	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

SIGN HERE  Signature *Michael Ciravolo* Date 2/13/04

Printed Name and Title

Richard Dietl, Chairman

Form LD-2 (Rec. 4/03)

Page 2

**Pharmaceutical Research and
Manufacturers of America**

Registrant Name Beau Dietl and Associates Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

H.R. 616	H.R. 2427	H.R. 2717	S.B.477
H.R. 780	H.R. 2491	H.R. 3710	S.B. 1225
H.R. 847	H.R. 2497	S.B. 7	
H.R. 1733	H.C.R. 225	S.B. 54	

Please see attached

17. House(s) of Congress and Federal agencies contacted Check if None


House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Richard Dietl	
Michael Ciravolo	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

**SIGN
HERE**



[Handwritten Signature]

Date 2/13/04

Printed Name and Title **Richard Dietl, Chairman**

Form LD-2 (Rec. 4/03)

Page 3

**Pharmaceutical Research and
Manufacturers of America**

Registrant Name Beau Dietl and Associates Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which th engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each co information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

H.R. 616	H.R. 2427	H.R. 2717	S.B.477
H.R. 780	H.R. 2491	H.R. 3710	S.B. 1225
H.R. 847	H.R. 2497	S.B. 7	
H.R. 1733	H.C.R. 225	S.B. 54	
Please see attached			

17. House(s) of Congress and Federal agencies contacted Check if None


House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Richard Dietl	
Michael Ciravolo	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

**SIGN
HERE**



Richard Dietl

Date 2/13/04

**Pharmaceutical Research and
Manufacturers of America**

Registrant Name Beau Dietl and Associates Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which th engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each co information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

H.R. 616	H.R. 2427	H.R. 2717	S.B.477
H.R. 780	H.R. 2491	H.R. 3710	S.B. 1225
H.R. 847	H.R. 2497	S.B. 7	
H.R. 1733	H.C.R. 225	S.B. 54	
Please see attached			


17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives Senate
--

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Richard Dietl	
Michael Ciravolo	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

SIGN HERE  Date 2/13/04

ATTACHMENT**Federal Lobbying Report****Period Covered: July 1, 2003 through December 31, 2003****Due: February 15, 2004****Registrant-Beau Dietl and Associates****Client-Pharmaceutical Research and Manufacturers of America**

Section 16. Specific lobbying issues	
H.R. 616	<p>Prescription Drug Affordability Act</p> <p>To amend the Internal Revenue Code of 1986 with respect to the purchase of prescription drugs by individuals who have attained retirement age, and to amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs and the sale of such drugs through Internet sites.</p>
H.R. 780	<p>Prescription Drug Price Reduction Act</p> <p>To amend the Federal Food, Drug, and Cosmetic Act to provide for the implementation of the program under section 804 of such Act, and for other purposes.</p>
H.R. 847	<p>Preserving Access to Safe, Affordable Canadian Medicines Act of 2003</p> <p>To amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs from Canada.</p>
H.R. 1733	<p>Senior Bill of Rights Act of 2003</p> <p>To amend XVIII and XIX of the Social Security Act to provide for a voluntary Medicare prescription medicine benefit, to provide greater access to affordable pharmaceuticals, to provide for substantial reductions in the cost of prescription drugs made available to Medicare beneficiaries, to amend the Internal Revenue Code of 1986 to disallow deductions for direct-to-consumer advertisement of prescription drugs, to amend the Federal Food, Drug, and Cosmetic Act to provide greater access to affordable pharmaceuticals and preserving access to safe affordable Canadian medicines, to amend the Federal Election Campaign Act of 1971 to prohibit campaign contributions by chief executive officers of pharmaceutical companies, and for other purposes.</p>
H.R. 2427	<p>Pharmaceutical Market Access Act of 2003</p> <p>To authorize the Secretary of Health and Human Services to promulgate regulations for the reimportation of prescription drugs, and for other purposes.</p>
H.R. 2491	<p>Greater Access to Affordable Pharmaceuticals Act</p> <p>(No further description provided)</p>

ATTACHMENT**Federal Lobbying Report****Period Covered: July 1, 2003 through December 31, 2003****Due: February 15, 2004****Registrant-Beau Dietl and Associates
Client-Pharmaceutical Research and Manufacturers of America**

H.R. 2497	<p>Prescription Drug Parity for Americans Act</p> <p>To permit commercial importation of prescription drugs from Canada, and for other purposes.</p>
H.R. 2717	<p>Affordable Medicine Safety and Access Act</p> <p>To amend the Federal Food, Drug, and Cosmetic Act to establish a program to provide for the voluntary certification of Internet and mail-order pharmacies, to amend such Act to authorize, subject to certain conditions, the importation by individuals of prescription drugs from Canada for personal use, and for other purposes.</p>
H.R. 3710	<p>(No Short Title)</p> <p>To amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs.</p>
H.C.R. 225	<p>Expressing the sense of the Congress that the illegal importation of prescription drugs severely undermines the regulatory protections afforded to United States consumers, and for other purposes.</p>
S.B. 7	<p>Prescription Drug Benefit and Cost Containment Act of 2003</p> <p>To amend title XVIII of the Social Security Act to provide coverage of outpatient prescription drugs under the medicare program and to amend the Federal Food, Drug, and Cosmetic Act to provide greater access to affordable pharmaceuticals, and for other purposes.</p>
S.B. 54	<p>Greater Access to Affordable Pharmaceuticals Act of 2003</p> <p>To amend the Federal Food, Drug, and Cosmetic Act to provide greater access to affordable pharmaceuticals.</p>
S.B. 477	<p>Preserving Prescription Drug Discounts Act</p> <p>To amend the Internal Revenue Code of 1986 to disallow deductions and credits for companies who discriminate against Canadian pharmacies that pass along discounts to consumers living in the United States.</p>
S.B. 1225	<p>Greater Access to Affordable Pharmaceuticals Act</p> <p>(No further description provided.)</p>

